ReviewMediterranean journal of rheumatology2026
Iguratimod in Autoimmune Diseases: Emerging Evidence for its Immunomodulatory and Therapeutic Role.
Review in Mediterranean journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disorder marked by joint inflammation and damage, leading to disability. Traditional treatments include methotrexate and other DMARDs, but many patients experience inadequate responses or intolerable side effects. Iguratimod (IGU), a novel synthetic DMARD developed in Japan, has shown promise in the management of RA and related autoimmune conditions. Methodology: A comprehensive literature review was conducted using databases such as PubMed, Google Scholar, ScienceDirect, Web of Science, and Medline, focusing on recent high-quality publications related to iguratimod and employing keywords like "Iguratimod," "Sjögren's syndrome," "Sjögren's disease", "Rheumatoid arthritis," and "Ankylosing spondylitis". Results and Discussion: Clinical trials have demonstrated that iguratimod effectively reduces disease activity in RA patients, showing a comparable efficacy to salazosulphapyridine and improved outcomes when combined with methotrexate. In patients with Sjögren's disease, IGU significantly decreased disease activity indices and immunoglobulin levels. Furthermore, studies indicate that IGU has a favourable safety profile with fewer adverse effects than traditional DMARDs. The findings suggest that IGU offers a viable alternative for patients with RA and other autoimmune diseases who are intolerant to conventional therapies. Its dual action as an immunomodulator and anti-inflammatory agent positions it as a beneficial option for managing these chronic conditions. Conclusion: Iguratimod is a promising therapeutic option for the treatment of rheumatoid arthritis, Sjögren's disease, and ankylosing spondylitis. Further research is warranted to establish long-term efficacy and safety profiles and explore its potential in combination therapies for patients with inadequate responses to existing treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.